ホーム › トリプルネガティブ乳がん › ワシントン
ワシントンにおけるトリプルネガティブ乳がんの臨床試験
ワシントン内の拠点で、トリプルネガティブ乳がんに関する20件の研究が参加者を募集しています。
ワシントン内の都市
公式研究テキスト（英語）
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Fred Hutchinson Cancer Center ( Site 0069), Seattle
- Cancer Care Northwest ( Site 0003), Spokane
- Northwest Medical Specialties, PLLC ( Site 0067), Tacoma
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Fred Hutchinson Cancer Center, Seattle
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Northwest Medical Specialties, PLLC ( Site 0093), Tacoma
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Fred Hutchinson Cancer Center ( Site 0042), Seattle
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06841354A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Swedish Medical Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06618287Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- University of Washington Fred Hutchinson, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Providence Regional Cancer System, Lacey
- MultiCare Regional Cancer Center - Tacoma, Puyallup
- Northwest Medical Specialties, PLLC, Puyallup
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Cancer Care Northwest, Spokane Valley
被験者募集中観察研究
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07211178SMP-3124LP in Adults With Advanced Solid Tumors
- University of Washington, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06526819A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07078604Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Swedish Cancer Institute, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- University Of Washington, Seattle
被験者募集中第1相
18歳〜100歳 · 全性別 · 2026/07/29更新 · NCT06562192A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Summit Cancer Center, Spokane
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/28更新 · NCT06150664A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
- Summit Cancer Centers, Spokane
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Medical Oncology Associates, Spokane
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/18更新 · NCT07503808A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Fred Hutch Cancer Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/09/09更新 · NCT06682793A Study of NX-1607 in Adults With Advanced Malignancies
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/09更新 · NCT05107674CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Cancer Care Northwest, Spokane
被験者募集中観察研究
18歳以上 · 女性 · 2025/01/07更新 · NCT06230185ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。